Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UCB sells anti-haemorrhagic drug to Eumedica
Somatostatine-UCB is indicated for the treatment of acute upper gastrointestinal bleeding resulting from gastric and duodenal ulcers and other. UCB receives a cash consideration of an industry average
Somatostatine-UCB is indicated for the treatment of acute upper gastrointestinal bleeding resulting from gastric and duodenal ulcers and other. UCB receives a cash consideration of an industry average
As one of the first companies to file an abbreviated new drug application containing a paragraph IV certification for this product, Teva has obtained a 180-day period of
The 40 patient single-blinded clinical trial was conducted in the EU. It was designed to demonstrate DM-99’s effectiveness at changing blood glucose levels in patients diagnosed with type
Under the terms of the agreement, Bioceros will be a pre-approved cell line generation partner for licensees of the PER.C6 cell line located in the EU. Other terms
This study is a randomized blinded study comparing the rates of gastric and duodenal mucosal damage, measured by endoscopy, between PL 2200 and 325mg aspirin at the preferred
Under the terms of the agreement, GlaxoSmithKline (GSK) will assume all development responsibility and associated costs for IDX899, and Idenix will receive an upfront payment of $34 million
PPD has licensed the development rights for dapoxetine to Alza, a Janssen-Cilag affiliate. Under terms of the agreement, PPD will receive a $2.5 million milestone payment for each
The clinical trial is a Phase IIa double blind, placebo controlled, multi-center dose ranging study to evaluate the safety and preliminary efficacy of AZX100 in trocar sites of
Dr Schoenberg will assist the company in its current effort to complete critical clinical trials with the Sonablate 500 technology in the treatment of patients with prostate cancer.
The Cayman product family is comprised of multiple implant systems, including a buttress plate to address graft expulsion, a lower lumbar sacral plate, and additional plating designs to